KR101556808B1 - 비씨클로-치환된 피라졸론 아조 유도체, 그 제조 방법 및 약학적 용도 - Google Patents
비씨클로-치환된 피라졸론 아조 유도체, 그 제조 방법 및 약학적 용도 Download PDFInfo
- Publication number
- KR101556808B1 KR101556808B1 KR1020107017630A KR20107017630A KR101556808B1 KR 101556808 B1 KR101556808 B1 KR 101556808B1 KR 1020107017630 A KR1020107017630 A KR 1020107017630A KR 20107017630 A KR20107017630 A KR 20107017630A KR 101556808 B1 KR101556808 B1 KR 101556808B1
- Authority
- KR
- South Korea
- Prior art keywords
- mixture
- mmol
- carboxylic acid
- methyl
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *C(c1ccc(N)[o]1)=O Chemical compound *C(c1ccc(N)[o]1)=O 0.000 description 3
- DOCJCJIGBWVFQF-QLYXXIJNSA-N CC(/C(/C1=O)=N/Nc(cccc2-c3c[s]c(C(O)=O)c3)c2O)=NN1c1cc(CCC2)c2cc1 Chemical compound CC(/C(/C1=O)=N/Nc(cccc2-c3c[s]c(C(O)=O)c3)c2O)=NN1c1cc(CCC2)c2cc1 DOCJCJIGBWVFQF-QLYXXIJNSA-N 0.000 description 2
- BEHQZXALCYVEOZ-QYQHSDTDSA-N CC(/C(/C1=O)=N/Nc(cccc2-c3ccc(C(O)=O)[s]3)c2O)=NN1c1cc(CCCC2)c2cc1 Chemical compound CC(/C(/C1=O)=N/Nc(cccc2-c3ccc(C(O)=O)[s]3)c2O)=NN1c1cc(CCCC2)c2cc1 BEHQZXALCYVEOZ-QYQHSDTDSA-N 0.000 description 2
- WITKGWRONMFQRY-FAJYDZGRSA-N CC(C)(CC1)c2c1ccc(N(C1=O)N=C(C)/C1=N/Nc(cc(C)cc1-c3ccc(C(O)=O)[s]3)c1O)c2 Chemical compound CC(C)(CC1)c2c1ccc(N(C1=O)N=C(C)/C1=N/Nc(cc(C)cc1-c3ccc(C(O)=O)[s]3)c1O)c2 WITKGWRONMFQRY-FAJYDZGRSA-N 0.000 description 2
- SGALMGILCDDTQI-GDWJVWIDSA-N CC(C)(CC1)c2c1ccc(N(C1=O)N=C(C)/C1=N/Nc(cc(C)cc1-c3cccc(C(O)=O)c3)c1O)c2 Chemical compound CC(C)(CC1)c2c1ccc(N(C1=O)N=C(C)/C1=N/Nc(cc(C)cc1-c3cccc(C(O)=O)c3)c1O)c2 SGALMGILCDDTQI-GDWJVWIDSA-N 0.000 description 2
- RNRAWOMVIZHUQC-QYQHSDTDSA-N CC(CC1)c2c1ccc(N(C1=O)N=C(C)/C1=N/Nc(cccc1-c3ccc(C(O)=O)[o]3)c1O)c2 Chemical compound CC(CC1)c2c1ccc(N(C1=O)N=C(C)/C1=N/Nc(cccc1-c3ccc(C(O)=O)[o]3)c1O)c2 RNRAWOMVIZHUQC-QYQHSDTDSA-N 0.000 description 2
- DVNVHYZCRZPUIM-UHFFFAOYSA-N CC1(C)c2cc(N3N=C(C)CC3=O)ccc2CC1 Chemical compound CC1(C)c2cc(N3N=C(C)CC3=O)ccc2CC1 DVNVHYZCRZPUIM-UHFFFAOYSA-N 0.000 description 2
- LCFMHMLKNSJRNG-MKFPQRGTSA-N CC(C)(CC1(C)C)c(cc2)c1cc2N(C1=O)N=C(C)/C1=N/Nc(cc(C)cc1-c2cccc(C(O)=O)c2)c1O Chemical compound CC(C)(CC1(C)C)c(cc2)c1cc2N(C1=O)N=C(C)/C1=N/Nc(cc(C)cc1-c2cccc(C(O)=O)c2)c1O LCFMHMLKNSJRNG-MKFPQRGTSA-N 0.000 description 1
- AJNGYKJVXWONGA-UHFFFAOYSA-N CC(CC1=O)=NN1c1cc(CCCC2)c2cc1 Chemical compound CC(CC1=O)=NN1c1cc(CCCC2)c2cc1 AJNGYKJVXWONGA-UHFFFAOYSA-N 0.000 description 1
- HLSKTUANRGHHGI-UHFFFAOYSA-N CC(CC1=O)=NN1c1ccc(CCC2)c2c1 Chemical compound CC(CC1=O)=NN1c1ccc(CCC2)c2c1 HLSKTUANRGHHGI-UHFFFAOYSA-N 0.000 description 1
- JUTDHLQZZORZJS-UHFFFAOYSA-N CC1c2cc(N3N=C(C)CC3=O)ccc2CC1 Chemical compound CC1c2cc(N3N=C(C)CC3=O)ccc2CC1 JUTDHLQZZORZJS-UHFFFAOYSA-N 0.000 description 1
- LVQZRICCCFSHGG-UHFFFAOYSA-N Cc(cc1N)cc(-c2cc(C(O)=O)ccc2)c1O Chemical compound Cc(cc1N)cc(-c2cc(C(O)=O)ccc2)c1O LVQZRICCCFSHGG-UHFFFAOYSA-N 0.000 description 1
- WLYUEIAYLSVNTG-UHFFFAOYSA-N Cc(cc1N)cc(-c2ccc(C(O)=O)[s]2)c1O Chemical compound Cc(cc1N)cc(-c2ccc(C(O)=O)[s]2)c1O WLYUEIAYLSVNTG-UHFFFAOYSA-N 0.000 description 1
- GINVIWCJMWWJNN-UHFFFAOYSA-N Nc1cccc(-c2c[s]c(C(O)=O)c2)c1O Chemical compound Nc1cccc(-c2c[s]c(C(O)=O)c2)c1O GINVIWCJMWWJNN-UHFFFAOYSA-N 0.000 description 1
- MWEHFNSBOUGDRG-UHFFFAOYSA-N Nc1cccc(-c2ccc(C(O)=O)[o]2)c1O Chemical compound Nc1cccc(-c2ccc(C(O)=O)[o]2)c1O MWEHFNSBOUGDRG-UHFFFAOYSA-N 0.000 description 1
- LWLQCLOEHJOGEL-UHFFFAOYSA-N Nc1cccc(-c2ccc(C(O)=O)[s]2)c1O Chemical compound Nc1cccc(-c2ccc(C(O)=O)[s]2)c1O LWLQCLOEHJOGEL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D231/08—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen or sulfur atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810000346.6 | 2008-01-10 | ||
| CNA2008100003466A CN101481352A (zh) | 2008-01-10 | 2008-01-10 | 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20100120141A KR20100120141A (ko) | 2010-11-12 |
| KR101556808B1 true KR101556808B1 (ko) | 2015-10-01 |
Family
ID=40878665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020107017630A Active KR101556808B1 (ko) | 2008-01-10 | 2009-01-04 | 비씨클로-치환된 피라졸론 아조 유도체, 그 제조 방법 및 약학적 용도 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8367710B2 (https=) |
| EP (1) | EP2236500B1 (https=) |
| JP (1) | JP5441269B2 (https=) |
| KR (1) | KR101556808B1 (https=) |
| CN (2) | CN101481352A (https=) |
| AU (1) | AU2009207966B2 (https=) |
| BR (1) | BRPI0907234B1 (https=) |
| CA (1) | CA2711535C (https=) |
| ES (1) | ES2533366T3 (https=) |
| MX (1) | MX2010007553A (https=) |
| PT (1) | PT2236500E (https=) |
| RU (1) | RU2488582C2 (https=) |
| UA (1) | UA101172C2 (https=) |
| WO (1) | WO2009092276A1 (https=) |
| ZA (1) | ZA201004794B (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0302486D0 (sv) * | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| CN101921232A (zh) * | 2009-06-11 | 2010-12-22 | 上海恒瑞医药有限公司 | 双环取代吡唑酮偶氮类衍生物的盐,其制备方法及其在医药上的应用 |
| JP5704073B2 (ja) * | 2009-10-23 | 2015-04-22 | 日産化学工業株式会社 | 縮環へテロ環化合物及びトロンボポエチンレセプター活性化剤 |
| CN103360317B (zh) * | 2012-04-11 | 2016-12-14 | 齐鲁制药有限公司 | 双环取代吡唑酮偶氮类衍生物、其制备方法及用途 |
| CN103724206A (zh) * | 2014-01-17 | 2014-04-16 | 青岛农业大学 | 化合物2-溴-4-氟-6-硝基苯酚的制备方法和农用生物活性 |
| WO2015111085A2 (en) * | 2014-01-27 | 2015-07-30 | Cadila Healthcare Limited | Processes for the preparation of eltrombopag and pharmaceutically acceptable salts, solvates and intermediates thereof |
| US9849077B2 (en) | 2014-03-10 | 2017-12-26 | Mary Kay Inc. | Skin lightening compositions |
| CN104592033A (zh) * | 2014-12-30 | 2015-05-06 | 杭州和泽医药科技有限公司 | 一种艾曲波帕关键中间体的合成方法 |
| CN106994120B (zh) * | 2016-01-22 | 2021-05-14 | 江苏恒瑞医药股份有限公司 | 一种含有双环取代吡唑酮偶氮类衍生物或其盐的药物组合物及其制备方法 |
| TW201726129A (zh) * | 2016-01-22 | 2017-08-01 | 江蘇恆瑞醫藥股份有限公司 | 一種含有雙環取代吡唑酮偶氮類衍生物或其鹽的藥物組成物及其製備方法 |
| TWI762556B (zh) * | 2017-01-19 | 2022-05-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種雙環取代吡唑酮偶氮類衍生物的製備方法及其中間體 |
| CN110028497B (zh) * | 2018-01-11 | 2020-11-17 | 江苏恒瑞医药股份有限公司 | 一种血小板生成素模拟物的乙醇胺盐的结晶形式及制备方法 |
| CN113226463A (zh) * | 2019-01-08 | 2021-08-06 | 江苏恒瑞医药股份有限公司 | 双环取代吡唑酮偶氮类衍生物的给药方案 |
| CN112062699B (zh) * | 2020-11-13 | 2021-02-26 | 苏州开元民生科技股份有限公司 | 一种邻氨基苯硫酚的制备方法 |
| WO2022228551A1 (zh) * | 2021-04-30 | 2022-11-03 | 江苏恒瑞医药股份有限公司 | 一种血小板生成素受体激动剂的给药方案 |
| US20250144077A1 (en) * | 2022-01-25 | 2025-05-08 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Dosage regimen for thrombopoietin receptor agonist |
| WO2025140275A1 (zh) * | 2023-12-25 | 2025-07-03 | 江苏恒瑞医药股份有限公司 | 取代吡唑啉偶氮衍生物的磷酸酯化合物或其可药用盐 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB775216A (en) * | 1954-02-23 | 1957-05-22 | Sandoz Ltd | Improvements in or relating to monoazo dyestuffs of the benzene-azo-pyrazolone series and their chromium-complex compounds |
| GB806709A (en) * | 1955-04-22 | 1958-12-31 | Bayer Ag | Monoazo dyestuffs of the benzene-azo-pyrazolone series and metal complexes thereof |
| TR199701526T1 (xx) | 1995-06-07 | 1998-03-21 | Glaxo Group Limited | Bir trombopoietin resept�r�ne ba�lanan peptitler ve bile�ikler. |
| US5869451A (en) | 1995-06-07 | 1999-02-09 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
| JPH111477A (ja) | 1997-06-12 | 1999-01-06 | Hokuriku Seiyaku Co Ltd | １，４−ベンゾジアゼピン誘導体及びその用途 |
| AU9265698A (en) | 1997-09-02 | 1999-03-22 | Boehringer Mannheim Gmbh | Mpl-receptor ligands, process for their preparation, medicaments containing themand their use for the treatment and prevention of thrombocytopaenia and anaemia |
| JP2002529502A (ja) | 1998-11-17 | 2002-09-10 | スミスクライン・ビーチャム・コーポレイション | 血小板減少症の治療法 |
| WO2000039773A1 (de) | 1998-12-14 | 2000-07-06 | Mannesmann Ag | Verfahren zur übertragung von verkehrsinformationen |
| GC0000177A (en) | 1998-12-17 | 2006-03-29 | Smithkline Beecham | Thrombopoietin mimetics |
| KR20020069183A (ko) | 1999-07-26 | 2002-08-29 | 시오노기세이야쿠가부시키가이샤 | 트롬보포이에틴 작동성을 나타내는 의약 조성물 |
| EP1213965B1 (en) | 1999-09-10 | 2006-01-18 | Smithkline Beecham Corporation | Thrombopoietin mimetics |
| WO2001034585A1 (en) | 1999-11-05 | 2001-05-17 | Smithkline Beecham Corporation | Semicarbazone derivatives and their use as thrombopoietin mimetics |
| AU2079901A (en) | 1999-12-06 | 2001-06-12 | Smithkline Beecham Corporation | Thrombopoietin mimetics |
| TWI284639B (en) | 2000-01-24 | 2007-08-01 | Shionogi & Co | A compound having thrombopoietin receptor agonistic effect |
| CY2010012I2 (el) * | 2000-05-25 | 2020-05-29 | Novartis Ag | Μιμητικα θρομβοποιητινης |
| TWI280128B (en) * | 2002-05-22 | 2007-05-01 | Smithkline Beecham Corp | 3'-[(2Z)-[1-(3,4- dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
| EP2387998A1 (en) * | 2003-04-29 | 2011-11-23 | Glaxosmithkline LLC | Methods for treating degenerative diseases/injuries |
| DE602004019685D1 (de) | 2003-12-26 | 2009-04-09 | Allergan Inc | DISUBSTITUIERTE CHALCOGENOXIME MIT ANTAGONISTISCHER WIRKUNG AM RAR(Gamma)-RETINOIDREZEPTOR |
| JP4518819B2 (ja) * | 2004-03-17 | 2010-08-04 | 富士フイルム株式会社 | アゾ化合物 |
| AU2005314788B2 (en) * | 2004-12-14 | 2011-09-22 | Nissan Chemical Industries, Ltd. | Amide compound and thrombopoietin receptor activator |
| JP2009511603A (ja) * | 2005-10-13 | 2009-03-19 | スミスクライン・ビーチャム・コーポレイション | 貯蔵中の血小板の有効性を維持する方法 |
| CA2630234A1 (en) * | 2005-11-23 | 2007-05-31 | Ligand Pharmaceuticals Inc. | Thrombopoietin activity modulating compounds and methods |
-
2008
- 2008-01-10 CN CNA2008100003466A patent/CN101481352A/zh active Pending
-
2009
- 2009-01-04 ES ES09703490.4T patent/ES2533366T3/es active Active
- 2009-01-04 PT PT97034904T patent/PT2236500E/pt unknown
- 2009-01-04 WO PCT/CN2009/000001 patent/WO2009092276A1/zh not_active Ceased
- 2009-01-04 US US12/812,119 patent/US8367710B2/en active Active
- 2009-01-04 AU AU2009207966A patent/AU2009207966B2/en active Active
- 2009-01-04 CA CA2711535A patent/CA2711535C/en active Active
- 2009-01-04 CN CN2009800001980A patent/CN101679286B/zh active Active
- 2009-01-04 EP EP09703490.4A patent/EP2236500B1/en active Active
- 2009-01-04 MX MX2010007553A patent/MX2010007553A/es active IP Right Grant
- 2009-01-04 UA UAA201008616A patent/UA101172C2/ru unknown
- 2009-01-04 BR BRPI0907234-9A patent/BRPI0907234B1/pt active IP Right Grant
- 2009-01-04 KR KR1020107017630A patent/KR101556808B1/ko active Active
- 2009-01-04 JP JP2010541680A patent/JP5441269B2/ja active Active
- 2009-01-04 RU RU2010127786/04A patent/RU2488582C2/ru active
-
2010
- 2010-07-07 ZA ZA2010/04794A patent/ZA201004794B/en unknown
-
2013
- 2013-01-16 US US13/742,633 patent/US20130123507A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP5441269B2 (ja) | 2014-03-12 |
| BRPI0907234B1 (pt) | 2021-08-10 |
| JP2011509263A (ja) | 2011-03-24 |
| PT2236500E (pt) | 2015-04-07 |
| RU2010127786A (ru) | 2012-02-20 |
| CA2711535C (en) | 2015-12-15 |
| BRPI0907234A2 (pt) | 2020-08-04 |
| KR20100120141A (ko) | 2010-11-12 |
| ES2533366T3 (es) | 2015-04-09 |
| CN101679286A (zh) | 2010-03-24 |
| US20100316601A1 (en) | 2010-12-16 |
| RU2488582C2 (ru) | 2013-07-27 |
| WO2009092276A1 (zh) | 2009-07-30 |
| EP2236500B1 (en) | 2014-12-24 |
| HK1134818A1 (en) | 2010-05-14 |
| AU2009207966A1 (en) | 2009-07-30 |
| MX2010007553A (es) | 2010-10-04 |
| EP2236500A1 (en) | 2010-10-06 |
| CA2711535A1 (en) | 2009-07-30 |
| CN101481352A (zh) | 2009-07-15 |
| EP2236500A4 (en) | 2012-08-22 |
| CN101679286B (zh) | 2011-06-08 |
| UA101172C2 (ru) | 2013-03-11 |
| US20130123507A1 (en) | 2013-05-16 |
| AU2009207966B2 (en) | 2013-03-21 |
| US8367710B2 (en) | 2013-02-05 |
| ZA201004794B (en) | 2011-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101556808B1 (ko) | 비씨클로-치환된 피라졸론 아조 유도체, 그 제조 방법 및 약학적 용도 | |
| JP2011509263A5 (https=) | ||
| JP3813875B2 (ja) | トロンボポエチン摸倣物 | |
| KR101738181B1 (ko) | 바이사이클로-치환된 피라졸론 아조 유도체의 염, 이의 제조 방법 및 용도 | |
| AU2001274938A1 (en) | Thrombopoietin mimetics | |
| EP1156804A1 (en) | Thrombopoietin mimetics | |
| EP1244446A1 (en) | Thrombopoietin mimetics | |
| US20130078213A1 (en) | Thrombopoietin mimetics | |
| TWI437985B (zh) | 雙環取代吡唑酮偶氮類衍生物、其製備方法及其在醫藥上的應用 | |
| HK1134818B (en) | Bicyclo-substituted pyrazolon azo derivatives, preparation process and pharmaceutical use thereof | |
| HK1117825B (en) | Thrombopoietin mimetics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| FPAY | Annual fee payment |
Payment date: 20180920 Year of fee payment: 4 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20190919 Year of fee payment: 5 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 5 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 6 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 7 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-5-5-R10-R13-asn-PN2301 St.27 status event code: A-5-5-R10-R11-asn-PN2301 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 8 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 9 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 10 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 11 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 11 |